Alexandra Bercow
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Alexandra Bercow has a total of 75 co-authors. Here are the top co-authors by number of shared publications:
Alexander Melamed
From the Department of Radiology, Division of Abdominal Imaging (B.V., T.P.) and Gillette Center for Women’s Cancers (A.B., A.M.), Massachusetts General Hospital, 55 Fruit St, White 270, Boston, MA 02114
2 shared publications- Alexander Melamed
Massachusetts General Hospital, Boston, MA
2 shared publications - Eric L. Eisenhauer
Massachusetts General Hospital, Boston, MA, United States
2 shared publications - Jose Alejandro Rauh-Hain
Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
2 shared publications Kaitlyn James
Deborah Kelly Center for Clinical Research, Vincent Department of Obstetrics and Gynecology, Massachusetts General Hospital, Boston, Massachusetts, USA
2 shared publicationsL.W. Rice
University of Wisconsin School of Medicine and Public Health, Madison, WI, USA
2 shared publications
Latest Publications
- 25 July 2025
- Published by Elsevier in International Journal of Gynecological Cancer
- Vol. 35 (10) , 102018
Survival outcomes in patients with recurrent mixed sex cord-stromal tumors of the ovary
- 25 July 2025
- Published by Elsevier in International Journal of Gynecological Cancer
- Vol. 35 (10) , 102018
Survival outcomes in patients with recurrent mixed sex cord-stromal tumors of the ovary
- 1 November 2024
- Published by Radiological Society of North America (RSNA) in Radiology: Imaging Cancer
- Vol. 6 (6) , e240162
Nonpuerperal Uterine Inversion
- 1 November 2024
- Published by Radiological Society of North America (RSNA) in Radiology: Imaging Cancer
- Vol. 6 (6) , e240162
Nonpuerperal Uterine Inversion
- 10 August 2024
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 42 (23) , 2731-2735
Role of Minimally Invasive Techniques in the Management of Early-Stage Carcinoma of the Uterine Cervix
The Oncology Grand Rounds series is designed to place original reports published in the Journal into clinical context. A case presentation is followed by a description of diagnostic and management challenges, a review of the relevant literature, and a summary of the authors’ suggested management approaches. The goal of this series is to help readers better understand how to apply the results of key studies, including those published in Journal of Clinical Oncology , to patients seen in their own clinical practice.
- 10 August 2024
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 42 (23) , 2731-2735
Role of Minimally Invasive Techniques in the Management of Early-Stage Carcinoma of the Uterine Cervix
The Oncology Grand Rounds series is designed to place original reports published in the Journal into clinical context. A case presentation is followed by a description of diagnostic and management challenges, a review of the relevant literature, and a summary of the authors’ suggested management approaches. The goal of this series is to help readers better understand how to apply the results of key studies, including those published in Journal of Clinical Oncology , to patients seen in their own clinical practice.
- 11 August 2023
- Published by Elsevier in International Journal of Gynecological Cancer
- Vol. 33 (9) , 1434-1439
Patterns of spread and genetic alterations of primary endometrioid carcinomas of the ovary
Objective The primary objective was to characterize the rate of lymph node involvement in a cohort of patients with primary ovarian endometrioid adenocarcinoma. Additionally, we sought to quantify the recurrence rate, genetic alterations, and impact of lymphadenectomy on survival in this group of patients. Methods Patients diagnosed with primary endometrioid adenocarcinoma of the ovary without synchronous carcinomas of the female genital tract between 2012 and 2021 were identified. Demographic and disease-related data were collected from pathology reports and clinical records. Kaplan–Meier survival analysis using log rank test and Cox regression was performed. Results Sixty-three patients met inclusion criteria. Median age was 60 (range 22–90) years. Histologic grade was 1 in 20 (32%), 2 in 27 (43%), and 3 in 16 (25%) tumors. International Federation of Gynecology and Obstetrics (FIGO) stage after surgery included IA/B (n=20, 32%), IC (n=23, 37%), II (n=16, 25%), and III (n=4, 6%). Forty-one (65%) patients had pelvic and 33 (52%) had both pelvic and para-aortic lymphadenectomy. All assessed lymph nodes were negative for metastatic carcinoma. No patients with clinically pelvis-confined disease had tumors upstaged by either lymphadenectomy or omentectomy. Twenty-eight patients (44%) had germline mutational status documented; two had a germline BRCA mutation, confirmed to be pathogenic by molecular studies. Complete staging did not significantly impact progression free or overall survival, after adjusting for age and histologic grade in a Cox proportional hazards model. The recurrence rate was 15% for patients with grade 1 endometrioid carcinoma, 7% for grade 2, and 31% for grade 3, respectively. Conclusion There were no lymph node metastases in patients with comprehensively staged primary endometrioid ovarian carcinoma. Staging did not impact survival and may be omitted, regardless of grade. Germline BRCA mutations are rare in ovarian endometrioid carcinoma compared with reported rates in high-grade serous carcinomas.
- 11 August 2023
- Published by Elsevier in International Journal of Gynecological Cancer
- Vol. 33 (9) , 1434-1439
Patterns of spread and genetic alterations of primary endometrioid carcinomas of the ovary
Objective The primary objective was to characterize the rate of lymph node involvement in a cohort of patients with primary ovarian endometrioid adenocarcinoma. Additionally, we sought to quantify the recurrence rate, genetic alterations, and impact of lymphadenectomy on survival in this group of patients. Methods Patients diagnosed with primary endometrioid adenocarcinoma of the ovary without synchronous carcinomas of the female genital tract between 2012 and 2021 were identified. Demographic and disease-related data were collected from pathology reports and clinical records. Kaplan–Meier survival analysis using log rank test and Cox regression was performed. Results Sixty-three patients met inclusion criteria. Median age was 60 (range 22–90) years. Histologic grade was 1 in 20 (32%), 2 in 27 (43%), and 3 in 16 (25%) tumors. International Federation of Gynecology and Obstetrics (FIGO) stage after surgery included IA/B (n=20, 32%), IC (n=23, 37%), II (n=16, 25%), and III (n=4, 6%). Forty-one (65%) patients had pelvic and 33 (52%) had both pelvic and para-aortic lymphadenectomy. All assessed lymph nodes were negative for metastatic carcinoma. No patients with clinically pelvis-confined disease had tumors upstaged by either lymphadenectomy or omentectomy. Twenty-eight patients (44%) had germline mutational status documented; two had a germline BRCA mutation, confirmed to be pathogenic by molecular studies. Complete staging did not significantly impact progression free or overall survival, after adjusting for age and histologic grade in a Cox proportional hazards model. The recurrence rate was 15% for patients with grade 1 endometrioid carcinoma, 7% for grade 2, and 31% for grade 3, respectively. Conclusion There were no lymph node metastases in patients with comprehensively staged primary endometrioid ovarian carcinoma. Staging did not impact survival and may be omitted, regardless of grade. Germline BRCA mutations are rare in ovarian endometrioid carcinoma compared with reported rates in high-grade serous carcinomas.
- 1 February 2021
- Published by Elsevier in Current Problems in Cancer
- Vol. 45 (1) , 100622
Uterine artery pulsatility index and serum BMP-9 predict resistance to methotrexate therapy in gestational trophoblastic neoplasia: A cohort study
- 1 February 2021
- Published by Elsevier in Current Problems in Cancer
- Vol. 45 (1) , 100622
Uterine artery pulsatility index and serum BMP-9 predict resistance to methotrexate therapy in gestational trophoblastic neoplasia: A cohort study
- 1 January 2021
- Published by Elsevier in International Journal of Gynecological Cancer
- Vol. 31 (1) , 66-72
Palliative care referral patterns and measures of aggressive care at the end of life in patients with cervical cancer
Introduction Fifteen per cent of women with cervical cancer are diagnosed with advanced disease and carry a 5 year survival rate of only 17%. Cervical cancer may lead to particularly severe symptoms that interfere with quality of life, yet few studies have examined the rate of palliative care referral in this population. This study aims to examine the impact of palliative care referral on women who have died from cervical cancer in two tertiary care centers. Methods We conducted a retrospective review of cervical cancer decedents at two tertiary institutions from January 2000 to February 2017. We examined how aggressive measures of care at the end of life, metrics defined by the National Quality Forum, interacted with clinical variables to understand if end-of-life care was affected. Univariate and multivariate parametric and non-parametric testing was used, and linear regression models were generated to determine unadjusted and adjusted associations between aggressive measures of care at the end of life with receipt of palliative care as the main exposure. Results Of 153 cervical cancer decedents, 73 (47%) received a palliative care referral and the majority (57%) of referrals occurred during an inpatient admission. The median time from palliative care consultation to death was 2.3 months and 34% were referred to palliative care in the last 30 days of life. Palliative care referral was associated with fewer emergency department visits (OR 0.18, 95% CI 0.05 to 0.56), inpatient stays (OR 0.21, 95% CI 0.07 to 0.61), and intensive care unit admissions (OR 0.24, 95% CI 0.06 to 0.93) in the last 30 days of life. Palliative care did not affect chemotherapy or radiation administration within 14 days of death (p=0.36). Women evaluated by palliative care providers were less likely to die in the acute care setting (OR 0.19, 95% CI 0.07 to 0.51). Discussion In two tertiary care centers, less than half of cervical cancer decedents received palliative care consultations, and those referred to palliative care were often evaluated late in their disease course. Palliative care utilization was also associated with a lower incidence of poor-quality end-of-life care.
- 1 January 2021
- Published by Elsevier in International Journal of Gynecological Cancer
- Vol. 31 (1) , 66-72
Palliative care referral patterns and measures of aggressive care at the end of life in patients with cervical cancer
Introduction Fifteen per cent of women with cervical cancer are diagnosed with advanced disease and carry a 5 year survival rate of only 17%. Cervical cancer may lead to particularly severe symptoms that interfere with quality of life, yet few studies have examined the rate of palliative care referral in this population. This study aims to examine the impact of palliative care referral on women who have died from cervical cancer in two tertiary care centers. Methods We conducted a retrospective review of cervical cancer decedents at two tertiary institutions from January 2000 to February 2017. We examined how aggressive measures of care at the end of life, metrics defined by the National Quality Forum, interacted with clinical variables to understand if end-of-life care was affected. Univariate and multivariate parametric and non-parametric testing was used, and linear regression models were generated to determine unadjusted and adjusted associations between aggressive measures of care at the end of life with receipt of palliative care as the main exposure. Results Of 153 cervical cancer decedents, 73 (47%) received a palliative care referral and the majority (57%) of referrals occurred during an inpatient admission. The median time from palliative care consultation to death was 2.3 months and 34% were referred to palliative care in the last 30 days of life. Palliative care referral was associated with fewer emergency department visits (OR 0.18, 95% CI 0.05 to 0.56), inpatient stays (OR 0.21, 95% CI 0.07 to 0.61), and intensive care unit admissions (OR 0.24, 95% CI 0.06 to 0.93) in the last 30 days of life. Palliative care did not affect chemotherapy or radiation administration within 14 days of death (p=0.36). Women evaluated by palliative care providers were less likely to die in the acute care setting (OR 0.19, 95% CI 0.07 to 0.51). Discussion In two tertiary care centers, less than half of cervical cancer decedents received palliative care consultations, and those referred to palliative care were often evaluated late in their disease course. Palliative care utilization was also associated with a lower incidence of poor-quality end-of-life care.
- 29 July 2019
- Published by Wiley in Journal of Surgical Oncology
- Vol. 120 (5) , 864-872
Screening and surgical prophylaxis for hereditary cancer syndromes with high risk of endometrial and ovarian cancer
In the era of advanced cancer genomics, our recognition of hereditary cancer mutations continues to increase. Two of these conditions, which carry an increased risk of female cancers including endometrial, ovarian, breast, are hereditary breast and ovarian cancer syndrome and Lynch syndrome. Risk‐reducing surgery, such as mastectomy, salpingo‐oophorectomy, and hysterectomy may decrease cancer risk for mutation carriers. Background, indications, techniques, and consequences of these surgical procedures are reviewed.
- 29 July 2019
- Published by Wiley in Journal of Surgical Oncology
- Vol. 120 (5) , 864-872
Screening and surgical prophylaxis for hereditary cancer syndromes with high risk of endometrial and ovarian cancer
In the era of advanced cancer genomics, our recognition of hereditary cancer mutations continues to increase. Two of these conditions, which carry an increased risk of female cancers including endometrial, ovarian, breast, are hereditary breast and ovarian cancer syndrome and Lynch syndrome. Risk‐reducing surgery, such as mastectomy, salpingo‐oophorectomy, and hysterectomy may decrease cancer risk for mutation carriers. Background, indications, techniques, and consequences of these surgical procedures are reviewed.
- 1 June 2019
- Published by Elsevier in Gynecologic Oncology
- Vol. 154, 263
Age-related risk of postoperative mortality after cytoreductive surgery for advanced ovarian cancer
- 1 June 2019
- Published by Elsevier in Gynecologic Oncology
- Vol. 154, 263
Age-related risk of postoperative mortality after cytoreductive surgery for advanced ovarian cancer
- 1 June 2019
- Published by Elsevier in Gynecologic Oncology
- Vol. 153 (3) , e10-e11
Age-related risk of postoperative mortality after cytoreductive surgery for advanced ovarian cancer
- 1 June 2019
- Published by Elsevier in Gynecologic Oncology
- Vol. 153 (3) , e10-e11
Age-related risk of postoperative mortality after cytoreductive surgery for advanced ovarian cancer